查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1800245

癌症基因治療市場－2025年至2030年的預測

Cancer Gene Therapy Market - Forecasts fom 2025 to 2030
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 152 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

癌症基因治療市場預計將從 2025 年的 34.84 億美元成長到 2030 年的 85.61 億美元，複合年成長率為 19.70%。

受研發投入增加和全球癌症發病率上升的推動，癌症基因治療市場預計將在 2025 年至 2030 年期間經歷強勁成長。這個創新領域專注於修改癌細胞中的遺傳物質，以糾正缺陷基因、傳遞治療基因或增強免疫反應，從而為晚期癌症的長期緩解提供潛力。該市場受到基因編輯、溶瘤病毒療法和免疫療法的進步的驅動，並得到良好的法規環境和大量資金的支持。北美，尤其是美國，憑藉其先進的醫療基礎設施和較高的癌症發病率佔據主導地位。挑戰包括高昂的治療費用和複雜的法律規範。

市場促進因素

增加研發投入

大量的研發投入正在推動癌症基因治療的進步。 2023年，美國國立衛生研究院 (NIH) 為基因治療研究撥款超過10億美元，反映出其對基因療法在解決尚未滿足的癌症治療需求方面的潛力充滿信心。諸如Xcell Biosciences和aCGT Vector於2023年10月達成的合作，旨在開發和測試基因療法，這些合作正在推動創新和擴充性。此外，歐洲創新委員會 (EIC) 加速器等計畫的資助正在支持溶瘤病毒療法、嵌合體抗原受體 (CAR) T細胞療法等的臨床開發。 EIC加速器於2023年向Elicera Therapeutics AB提供了267萬美元。

癌症發生率上升

全球癌症發生率的上升推動了對創新治療方法的需求。預計到2023年，美國新增癌症病例將增加至192萬，凸顯了對有效治療的迫切需求。 CAR-T療法和溶瘤病毒療法等基因療法針對晚期腫瘤，提供個人化治療方案並提高緩解率。癌症盛行率的上升，加上傳統療法的局限性，使得基因療法成為一種創新療法，尤其適用於非肌肉浸潤性膀胱癌 (NMIBC) 和骨髓惡性腫瘤。

有利的法規環境

支持性法律規範，尤其是在美國，正在推動市場成長。 FDA 於 2023 年 12 月核准了Adstiladrin 用於治療非肌肉層性膀胱炎 (NMIBC)，並於 2023 年 5 月批准了 Vyjuvek 用於治療營養不良性先天性水皰症，這表明該公司致力於加快創新療法的研發。 FDA 還簡審類，例如 REGENXBIO 公司於 2023 年 4 月批准了 RGX-202 用於治療Duchenne氏肌肉失養症營養不良症，這進一步簡化了研發流程並加快了市場發展。

市場限制

高昂的治療費用，例如Bluebird Bio公司於2023年8月核准的基因療法，其標價高達280萬美元，限制了患者和醫療保健系統的可及性。基因改造需要大量的臨床檢驗和合規性，而其複雜的法律規範和倫理擔憂也阻礙了治療進展。此外，供應鏈壓力，包括對脂質前驅物和質體DNA等關鍵原料徵收關稅，可能會增加生產成本並減緩可擴展性。

目錄

第1章執行摘要

第2章市場概述

  • 市場概覽
  • 市場定義
  • 調查範圍
  • 市場區隔

第3章 經營狀況

  • 市場促進因素
  • 市場限制
  • 市場機會
  • 波特五力分析
  • 產業價值鏈分析
  • 政策法規
  • 策略建議

第4章 技術展望

第5章 癌症基因治療市場（依治療類型）

  • 介紹
  • 免疫療法
  • 溶瘤病毒療法
  • 基因轉移
  • 其他

第6章 癌症基因治療市場（依載體型）

  • 介紹
  • 病毒性的
  • 非病毒

第7章 癌症基因治療市場（依癌症類型）

  • 介紹
  • 胸部
  • 肺
  • 胰臟
  • 攝護腺
  • 其他

第 8 章癌症基因治療市場（按最終用戶）

  • 介紹
  • 醫院和診所
  • 診斷和研究機構
  • 其他

第9章 癌症基因治療市場（按地區）

  • 介紹
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 西班牙
    • 其他
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 以色列
    • 其他
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 韓國
    • 印尼
    • 泰國
    • 其他

第10章競爭格局及分析

  • 主要企業和策略分析
  • 市場佔有率分析
  • 合併、收購、協議和合作
  • 競爭對手儀表板

第11章：公司簡介

  • Shanghai Sunway Biotech Co. Ltd
  • Amgen Inc.
  • Novartis
  • Gilead Sciences, Inc.
  • Bluebirdbio, Inc
  • Bristol Myers Squibb
  • GlaxoSmithKline plc
  • ElevateBio
  • Sangamo Therapeutics
  • BeiGene Ltd.

第12章調查方法

簡介目錄
Product Code: KSI061612055

The cancer gene therapy market is expected to grow from USD 3.484 billion in 2025 to USD 8.561 billion in 2030, at a CAGR of 19.70%.

The cancer gene therapy market is projected to experience robust growth from 2025 to 2030, driven by increasing research and development (R&D) investments and the rising global incidence of cancer. This innovative field focuses on modifying genetic material within cancer cells to correct defective genes, introduce therapeutic genes, or enhance immune responses, offering potential for long-term remission in advanced cancers. The market is propelled by advancements in gene editing, oncolytic virotherapy, and immunotherapy, supported by favorable regulatory environments and significant funding. North America, particularly the United States, dominates due to its advanced healthcare infrastructure and high cancer prevalence. Challenges include high treatment costs and complex regulatory frameworks.

Market Drivers

Increasing Research and Development Investments

Significant R&D investments are fueling advancements in cancer gene therapy. In 2023, the National Institutes of Health (NIH) allocated over $1 billion for gene therapy research, reflecting strong confidence in its potential to address unmet cancer treatment needs. Collaborations, such as the partnership between Xcell Biosciences and aCGT Vector in October 2023 to develop and test gene therapies, are enhancing innovation and scalability. Additionally, funding from programs like the European Innovation Council (EIC) Accelerator, which provided Elicera Therapeutics AB with $2.67 million in 2023, supports clinical development, particularly for oncolytic virotherapy and chimeric antigen receptor (CAR) T-cell therapies.

Rising Cancer Incidence

The global cancer burden is escalating, driving demand for innovative therapies. In the United States, new cancer cases rose to 1.92 million in 2023, underscoring the urgent need for effective treatments. Gene therapies, such as CAR-T and oncolytic virotherapy, target advanced-stage tumors and offer personalized solutions, enhancing remission rates. The growing prevalence of cancer, combined with the limitations of conventional treatments, positions gene therapy as a transformative approach, particularly for cancers like non-muscle-invasive bladder cancer (NMIBC) and hematological malignancies.

Favorable Regulatory Environment

Supportive regulatory frameworks, particularly in the United States, are accelerating market growth. The FDA's approval of therapies like Adstiladrin in December 2023 for NMIBC and Vyjuvek in May 2023 for dystrophic epidermolysis bullosa demonstrates a commitment to expediting innovative treatments. The FDA's fast-track designations, such as for REGENXBIO's RGX-202 for Duchenne muscular dystrophy in April 2023, further streamline development, encouraging market expansion.

Market Restraints

High treatment costs, such as the $2.8 million price tag for Bluebird Bio's gene therapy approved in August 2023, pose significant affordability challenges, limiting access for patients and healthcare systems. Complex regulatory frameworks and ethical concerns surrounding genetic modifications also hinder progress, requiring extensive clinical validation and compliance. Additionally, supply chain pressures, including tariffs on critical raw materials like lipid precursors and plasmid DNA, increase production costs and may delay scalability.

Market Segmentation

By Therapy Type

The market includes gene-induced immunotherapy, oncolytic virotherapy, and gene transfer therapy. Immunotherapy dominates due to its effectiveness in enhancing immune responses, with CAR-T therapies like Kymriah and Yescarta leading in hematological cancers. Oncolytic virotherapy is gaining traction for its dual action of destroying cancer cells and stimulating immunity.

By Vector Type

Viral vectors, particularly adeno-associated viruses (AAV) and lentiviruses, lead due to their high efficacy in gene delivery. Non-viral vectors, such as oligonucleotides, are emerging but hold a smaller share.

By Geography

North America, led by the United States, holds the largest market share, driven by a 36.5% valuation of $1.3 billion in 2023, robust R&D, and high cancer prevalence. Asia-Pacific is the fastest-growing region, with a projected CAGR of 27.2% in 2025, fueled by increasing healthcare investments in China, Japan, and India.

The cancer gene therapy market is set for significant growth from 2025 to 2030, driven by rising R&D investments, increasing cancer incidence, and supportive regulations. Despite challenges like high costs and regulatory complexities, advancements in immunotherapy and oncolytic virotherapy, coupled with strategic collaborations, are reshaping cancer treatment. North America leads, while Asia-Pacific's rapid growth signals global expansion. Industry players must focus on cost-effective innovations and scalable manufacturing to meet rising demand.

Key Benefits of this Report:

  • Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, and other sub-segments.
  • Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
  • Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape future market developments.
  • Actionable Recommendations: Utilize the insights to exercise strategic decisions to uncover new business streams and revenues in a dynamic environment.
  • Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

  • Historical data from 2020 to 2024 & forecast data from 2025 to 2030
  • Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, and Trend Analysis
  • Competitive Positioning, Strategies, and Market Share Analysis
  • Revenue Growth and Forecast Assessment of segments and regions including countries
  • Company Profiling (Strategies, Products, Financial Information, and Key Developments among others.

Segmentation:

By Therapy Type

  • Immunotherapy
  • Oncolytic Virotherapy
  • Gener Transfer
  • Others

By Vector Type

  • Viral
  • Non-Viral

By Cancer Type

  • Breast
  • Lungs
  • Pancreas
  • Prostate
  • Others

By End-User

  • Hospitals & Clinics
  • Diagnostic & Research Institutes
  • Others

By Geography

  • North America
  • United States
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • United Kingdom
  • Germany
  • France
  • Spain
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Others
  • Asia Pacific
  • Japan
  • China
  • India
  • South Korea
  • Indonesia
  • Thailand
  • Others

TABLE OF CONTENTS

1. EXECUTIVE SUMMARY

2. MARKET SNAPSHOT

  • 2.1. Market Overview
  • 2.2. Market Definition
  • 2.3. Scope of the Study
  • 2.4. Market Segmentation

3. BUSINESS LANDSCAPE

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Porter's Five Forces Analysis
  • 3.5. Industry Value Chain Analysis
  • 3.6. Policies and Regulations
  • 3.7. Strategic Recommendations

4. TECHNOLOGICAL OUTLOOK

5. CANCER GENE THERAPY MARKET BY THERAPY TYPE

  • 5.1. Introduction
  • 5.2. Immunotherapy
  • 5.3. Oncolytic Virotherapy
  • 5.4. Gene Transfer
  • 5.5. Others

6. CANCER GENE THERAPY MARKET BY VECTOR TYPE

  • 6.1. Introduction
  • 6.2. Viral
  • 6.3. Non-Viral

7. CANCER GENE THERAPY MARKET BY CANCER TYPE

  • 7.1. Introduction
  • 7.2. Breast
  • 7.3. Lungs
  • 7.4. Pancreas
  • 7.5. Prostate
  • 7.6. Others

8. CANCER GENE THERAPY MARKET BY END-USER

  • 8.1. Introduction
  • 8.2. Hospitals & Clinics
  • 8.3. Diagnostic & Research Institutes
  • 8.4. Others

9. CANCER GENE THERAPY MARKET BY GEOGRAPHY

  • 9.1. Introduction
  • 9.2. North America
    • 9.2.1. United States
    • 9.2.2. Canada
    • 9.2.3. Mexico
  • 9.3. South America
    • 9.3.1. Brazil
    • 9.3.2. Argentina
    • 9.3.3. Others
  • 9.4. Europe
    • 9.4.1. United Kingdom
    • 9.4.2. Germany
    • 9.4.3. France
    • 9.4.4. Spain
    • 9.4.5. Others
  • 9.5. Middle East & Africa
    • 9.5.1. Saudi Arabia
    • 9.5.2. UAE
    • 9.5.3. Israel
    • 9.5.4. Others
  • 9.6. Asia Pacific
    • 9.6.1. Japan
    • 9.6.2. China
    • 9.6.3. India
    • 9.6.4. South Korea
    • 9.6.5. Indonesia
    • 9.6.6. Thailand
    • 9.6.7. Others

10. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 10.1. Major Players and Strategy Analysis
  • 10.2. Market Share Analysis
  • 10.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 10.4. Competitive Dashboard

11. COMPANY PROFILES

  • 11.1. Shanghai Sunway Biotech Co. Ltd
  • 11.2. Amgen Inc.
  • 11.3. Novartis
  • 11.4. Gilead Sciences, Inc.
  • 11.5. Bluebirdbio, Inc
  • 11.6. Bristol Myers Squibb
  • 11.7. GlaxoSmithKline plc
  • 11.8. ElevateBio
  • 11.9. Sangamo Therapeutics
  • 11.10. BeiGene Ltd.

12. RESEARCH METHODOLOGY